BALA CYNWYD, PA / ACCESSWIRE / August 26, 2019 / Brodsky & Smith, LLC reminds investors of looming deadlines regarding its investigation of the following companies for violations of federal securities laws. If you purchased any of the below-listed stocks during the referenced time periods and want to discuss your legal rights, please contact Marc Ackerman, Esquire or Jordan Schatz, Esquire at 877-534-2590. There is no cost or financial obligation to you.

FRED’S, INC. (NASDAQ:FRED)

Shares purchased between December 20, 2016 and June 28, 2017

Deadline: August 27, 2019

According to the complaint, defendants made numerous materially false and misleading statements concerning the level of regulatory risk faced by the Original Merger and the Revised Merger which would ultimately cause the termination of the Fred’s Asset Purchase Agreement. Specifically, Defendants made false and/or misleading statements: (i) downplaying or disputing contrary reports from journalists signaling regulatory turbulence in closing the merger; (ii) representing that inside knowledge of the FTC gave confidence that the deal would close.

Additional information can be found at: http://www.brodskysmith.com/cases/freds-inc-nasdaq-fred/, or call: 877-534-2590. No cost or obligation.

ACER THERAPEUTICS INC. (NASDAQ:ACER)

Shares purchased between September 25, 2017 and June 24, 2019

Deadline: August 30, 2019

According to the complaint, defendants made false and/or misleading statements and/or failed to disclose that: (1) Acer lacked sufficient data to support filing EDSIVO’s NDA with the FDA for the treatment of vEDS; (2) the Ong Trial was an inadequate and ill-controlled clinical study by FDA standards, and was comprised of an insufficiently small group size to support EDSIVO’s NDA; (3) consequently, the FDA would likely reject EDSIVO’s NDA; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Additional information can be found at: http://www.brodskysmith.com/cases/acer-therapeutics-inc-nasdaq-acer/, or call: 877-534-2590. No cost or obligation to you.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

SOURCE: Brodsky & Smith, LLC

ReleaseID: 557437

ST. PETERSBURG, FL / ACCESSWIRE / August 26, 2019 / MMJ BioPharma Cultivation today has received notice from the DEA that its application for a DEA Schedule-I Bulk Manufacturer license is being processed for approval. Once awarded, the DEA approval will allow MMJ BioPharma Cultivation to cultivate cannabis plants to support MMJ International Holdings investigational new drug (IND) filings with the FDA for Multiple Sclerosis and Huntington’s disease.

The MMJ BioPharma Cultivation notice stated that the “DEA intends to propose regulations in the near future that would supersede the 2016 policy statement and govern persons seeking to become registered with the DEA to grow marijuana as bulk manufacturers, consistent with applicable law,” adding that the agency recognizes “the need to move past the single grower system and register additional growers.”

Attorney General William Barr voiced support for increasing the number of marijuana manufacturers in a press release today. He stated “I am pleased that the DEA is moving forward with its review of applications for those who seek to grow marijuana legally to support research.” “The Department of Justice will continue to work with our colleagues at the Department of Health and Human Services and across the Administration to improve research opportunities wherever we can.”

MMJ BioPharma Cultivation will meet the growing demand from hospitals, researchers, and scientist for their FDA/DEA approved research and clinical trials. MMJ BioPharma Cultivation will facilitate a process of scientific drug development and discovery governed by FDA protocol development processes and DEA regulatory manufacturing guidelines.

To further meet the statutory requirements of the “public benefit” MMJ BioPharma Cultivation has entered into an agreement with a US Native Indian Tribe to perform its development activities. MMJ BioPharma Cultivation is planning a phased development program on Native American Tribal Trust lands of approximately 1 million square feet with a state of the art extraction analytics lab to meet DEA approved researchers needs. MMJ BioPharma Cultivation will be employing tribal members in its development and cultivation program.

Dr. Elio Mariani, a senior executive of the company and big pharma veteran stated “we are looking forward to our collaboration with the tribe in unlocking the potential of cannabinoid medicines to address serious medical conditions. Our efforts will be guided by the FDA and DEA as we strive to produce the highest pharma grade plants and extracts for clinical research.”

Duane Boise, CEO of the company further stated, “At MMJ BioPharma Cultivation, we will grow quality and effective plant genetics as pharma grade medicine through the careful cultivation of cannabis plants. Our goal is to provide the purest, highest quality medicinal marijuana for the manufacture of FDA approved medicines and research.

CONTACT:

mmjbiopharma.com
media@mmjih.com
561-627-9455

SOURCE: MMJ BioPharma Cultivation

ReleaseID: 557515

LOS ANGELES, CA / ACCESSWIRE / August 26, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against L Brands, Inc. (“L Brands” or “the Company”) (NYSE:LB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. L Brands’ Victoria’s Secret and PINK stores experiencing worsening performance due in part to competing lingerie brands. The Company worked to drive sales through heavy promotional efforts such as offering customers discounts and free items. Although these tactics helped L Brands fight declines in sales, they impacted profit margins and cash flow negatively, also hurting the Company’s liquidity. When asked by market analysts about the sustainability of the Company’s dividend, executives replied that the Company “in its history, ha[d] never reduced the dividend.” Just weeks later, L Brands announced it was cutting its dividend in half to pay down debts. On this news, shares of L brands dropped by 18% on November 20, 2018. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about L Brands, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
Cell: 424-303-1964
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 557514

LOS ANGELES, CA / ACCESSWIRE / August 26, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CannTrust Holdings Inc. (“CannTrust” or “the Company”) (NYSE:CTST) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. CannTrust announced on July 8, 2019, that its greenhouse facility located in Ontario, Canada, was audited by Health Canada, which rated it “non-compliant.” Health Canada placed a hold on 5,200 kilograms of dried cannabis allegedly harvested from five unlicensed rooms. It will hold this cannabis until the Company is in compliance with regulations. CannTrust also announced it would hold another 7,500 kilograms of dried cannabis that it says was also produced in unlicensed rooms. Based on this news, shares of CannTrust fell by more than 21% in intraday trading on the same day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
310-301-3335
Cell: 424-303-1964
info@schallfirm.com
www.schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 557512

LOS ANGELES, CA / ACCESSWIRE / August 26, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against 3M Company (“3M” or “the Company”) (NYSE:MMM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between February 9, 2017 and May 28, 2019, inclusive (the ”Class Period”), are encouraged to contact the firm before September 27, 2019.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. 3M held overwhelming amounts of evidence internally documenting the toxic nature of its man-made chemicals or per- and polyfluoroalkyl substances (“PFAS”). The evidence, which spanned decades, matched claims by February 2018 claims by Minnesota’s Attorney General. The Company has a track record of downplaying negative information about PFAS. The Company’s knowledge has created significant legal exposure for the Company at multiple levels of government related to the intentional concealment of PFAS toxicity. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about 3M, investors suffered damages.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
Cell: 424-303-1964
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 557511

NEW YORK, NY / ACCESSWIRE / August 26, 2019 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Pluralsight, Inc. (NASDAQGS: PS)

Investors Affected : August 2, 2018 – July 31, 2019

A class action has commenced on behalf of certain shareholders in Pluralsight, Inc. According to the filed complaint, the Company failed to disclose that Pluralsight was experiencing substantial delays in hiring and properly training the salesforce necessary to meet its lofty billing projections. In addition, the Company knew at the time of the March 2019 secondary public offering (“SPO”) that it was behind schedule onboarding new sales representatives, which was hurting the Company’s sales execution and preventing Pluralsight from meeting its high growth projections. Instead of disclosing such facts at the time of the SPO, and to cash-out at inflated prices, Defendants intentionally obscured and omitted this pertinent information from investors.

Shareholders may find more information at https://securitiesclasslaw.com/securities/pluralsight-inc-loss-submission-form/?id=3183&from=1

Granite Construction Incorporated (NYSE: GVA)

Investors Affected : October 26, 2018 – August 1, 2019

A class action has commenced on behalf of certain shareholders in Granite Construction Incorporated. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company had assumed certain risks in connection with its heavy civil joint venture projects bid between 2012 and 2014; (2) there was an “untenable” imbalance of risk sharing between the Company and the joint venture project owners; (3) as a result, the Company was reasonably likely to incur additional project costs for its joint venture projects; (4) the Company was reasonably likely to incur additional costs in connection with certain project disputes; and (5) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects and prospects were materially misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://securitiesclasslaw.com/securities/granite-construction-incorporated-loss-submission-form/?id=3183&from=1

Valaris plc (NYSE: VAL)

Investors Affected : April 11, 2019 – July 31, 2019

A class action has commenced on behalf of certain shareholders in Valaris plc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the Company was plagued by a weak ultra-deepwater segment, massive cash usage, and significant negative cash flow; (ii) the foregoing was reasonably likely to have a material negative impact on the Company’s second quarter 2019 results; (iii) the merger leading to Valaris’s establishment could not deliver on its touted benefits; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/valaris-plc-loss-submission-form/?id=3183&from=1

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE: The Gross Law Firm

ReleaseID: 557496

LOS ANGELES, CA / ACCESSWIRE / August 26, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aclaris Therapeutics, Inc. (“Aclaris” or “the Company”) (NASDAQ:ACRS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. It was reported on June 20, 2019, that the FDA’s Office of Prescription Drug Promotion (OPDP) released a letter which stated that a video advertisement for Aclaris’s hydrogen peroxide topical solution, Eskata, “makes false or misleading claims” about its risk and efficacy. The FDA letter states that, “a direct-to-consumer video of an interview featuring a paid Aclaris spokesperson” was “especially concerning from a public health perspective because it fails to include information regarding the serious risks associated with Eskata, which bears warnings and precautions related to the risks of serious eye disorders . . . in the case of exposure to the eye and severe skin reactions including scarring.” Based on this news, shares of Aclaris fell significantly over the next two trading sessions.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
310-301-3335
Cell: 424-303-1964
info@schallfirm.com
www.schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 557495

LOS ANGELES, CA / ACCESSWIRE / August 26, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Abiomed, Inc. (“Abiomed” or “the Company”) (NASDAQ:ABMD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s shares between January 31, 2019 and July 31, 2019, inclusive (the ”Class Period”), are encouraged to contact the firm before October 7, 2019.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Abiomed suffered from declining revenue growth. The Company failed to develop a sufficient plan to rebuild its revenue growth. The Company did not have good prospects to increase its revenue growth over the next several fiscal quarters, leaving it likely to be forced to revise down its fiscal year 2020 guidance. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Abiomed, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
Cell: 424-303-1964
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 557494

LOS ANGELES, CA / ACCESSWIRE / August 26, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Evolent Health, Inc. (“Evolent” or “the Company”) (NYSE:EVH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s shares between March 3, 2017 and May 28, 2019, inclusive (the ”Class Period”), are encouraged to contact the firm before October 7, 2019.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Evolent’s partnership model was built from the ground up to inflate the Company’s revenue with huge fees and management expenses siphoned from operating partners including Passport. The partnership between Passport and Evolent quickly became unsustainable, especially when combined with complicating factors for Passport’s operations in Kentucky. Passport was left on the brink of insolvency due to the Company draining it of employees and money. In fact, Passport was selling itself off in a bidding process to avoid insolvency. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Evolent, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
Cell: 424-303-1964
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 557491

TORONTO, ON / ACCESSWIRE / August 26, 2019 / Avidian Gold Corp. (“Avidian” or the “Company”) (TSX-V:AVG) wishes to announce that the Board of Directors have approved the grant of 3,100,000 stock options (the “Options”) to certain members of management, directors and consultants of the Company. The Options granted will be issued in accordance with the Company’s current stock option plan.

The Options are exercisable into common shares of the Company at an exercise price of $0.20 per share and have a five-year term to maturity.

About Avidian Gold Corp.

Avidian brings a disciplined and veteran team of project managers together with a regional scale advanced stage gold-copper exploration portfolio in Alaska. Avidian’s Golden Zone project also hosts a NI 43-101 Indicated gold resource of 267,400 ounces (4,187,000 tonnes at 1.99 g/t Au) plus an Inferred gold resource of 35,900 ounces (1,353,000 tonnes at 0.83 g/t Au). Additional projects include Amanita which is adjacent to Kinross Gold’s Fort Knox gold mine in Alaska and Jungo and Dome Hill in Nevada. The Strickland and Black Raven properties, both located in Newfoundland, are held within Hide Tide Resources Corp, a private subsidiary company of Avidian.

Avidian is focused on and committed to the development of advanced stage mineral projects throughout first world mining friendly jurisdictions using industry best practices combined with a strong social license from local communities. Further details on the Corporation and the individual projects, including the NI 43-101 Technical report on the Golden Zone property, can be found on the Corporation’s website at www.avidiangold.com.

For further information, please contact:

Bonnie Hughes, Manger Investors Relation
Mobile: +44 7538 29674
Email: info@avidiangold.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

The technical information contained in this news release has been approved by Dr. Tom Setterfield, P.Geo., Vice President Exploration of Avidian, who is a Qualified Person as defined in National Instrument 43-101 – Standards of Disclosure for Mineral Projects.

Forward-looking information

This News Release includes certain “forward-looking statements”. These statements are based on information currently available to the Company and the Company provides no assurance that actual results will meet management’s expectations. Forward-looking statements include estimates and statements that describe the Company’s future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as “believes”, “anticipates”, “expects”, “estimates”, “may”, “could”, “would”, “will”, or “plan”. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results relating to, among other things, results of exploration, project development, reclamation and capital costs of the Company’s mineral properties, and the Company’s financial condition and prospects including the ability to close the Offering and secure additional financing as needed, could differ materially from those currently anticipated in such statements for many reasons such as: changes in general economic conditions and conditions in the financial markets; changes in demand and prices for minerals; litigation, legislative, environmental and other judicial, regulatory, political and competitive developments; technological and operational difficulties encountered in connection with the activities of the Company; and other matters discussed in this news release. This list is not exhaustive of the factors that may affect any of the Company’s forward-looking statements. These and other factors should be considered carefully and readers should not place undue reliance on the Company’s forward-looking statements. The Company does not undertake to update any forward-looking statement that may be made from time to time by the Company or on its behalf, except in accordance with applicable securities laws.

SOURCE: Avidian Gold Corp.

ReleaseID: 557489